Payment overview · 2025
General Payments
$92.11
3 reported records · 3 companies
Healthcare provider profile · identity verified
John D. Ingram, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DENISON, IA · NPI 1205838984
Verified facts
What the public records show
CMS Open Payments records show John D. Ingram, M.D. received $92.11 in general payments during 2025 across 3 reported records.
Lilly USA, LLC accounted for 62.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.51 | 62.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.64 | 21.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.96 | 16.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $92.11 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1036 | 180 |
| Omeprazole | Omeprazole | 1036 | 214 |
| Gabapentin | Gabapentin | 777 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 685 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 681 | 158 |
| Furosemide | Furosemide | 541 | 100 |
| Losartan Potassium | Losartan Potassium | 533 | 122 |
| Tamsulosin Hcl | Tamsulosin Hcl | 529 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 371 | 52 |
| Celecoxib | Celecoxib | 362 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 333 | 50 |
| Lisinopril | Lisinopril | 300 | 70 |
| Simvastatin | Simvastatin | 292 | 64 |
| Metformin Hcl Er | Metformin Hcl | 289 | 75 |
| Donepezil Hcl | Donepezil Hcl | 287 | 32 |
| Sertraline Hcl | Sertraline Hcl | 285 | 50 |
| Potassium Chloride | Potassium Chloride | 268 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 61 |
| Baclofen | Baclofen | 246 | 63 |
| Prednisone | Prednisone | 235 | 113 |
| Tramadol Hcl | Tramadol Hcl | 213 | 46 |
| Eliquis | Apixaban | 212 | 36 |
| Lorazepam | Lorazepam | 207 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 187 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 175 | 36 |
| Carvedilol | Carvedilol | 170 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 57 |
| Glipizide | Glipizide | 165 | 39 |
| Allopurinol | Allopurinol | 164 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 154 | 25 |
| Warfarin Sodium | Warfarin Sodium | 150 | 22 |
| Meloxicam | Meloxicam | 139 | 34 |
| Xarelto | Rivaroxaban | 136 | 25 |
| Ozempic | Semaglutide | 131 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 131 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 35 |
| Jantoven | Warfarin Sodium | 127 | 21 |
| Methotrexate | Methotrexate Sodium | 126 | 12 |
| Alendronate Sodium | Alendronate Sodium | 124 | 21 |
| Glipizide Er | Glipizide | 122 | 29 |
| Finasteride | Finasteride | 117 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 117 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 113 | 23 |
| Spironolactone | Spironolactone | 109 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 27 |
| Atenolol | Atenolol | 97 | 11 |
| Famotidine | Famotidine | 97 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 96 | 22 |
| Glimepiride | Glimepiride | 96 | 16 |
| Montelukast Sodium | Montelukast Sodium | 96 | 25 |
| Pregabalin | Pregabalin | 96 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 93 | 15 |
| Clonazepam | Clonazepam | 89 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 26 |
| Terazosin Hcl | Terazosin Hcl | 89 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 24 |
| Topiramate | Topiramate | 87 | 14 |
| Trazodone Hcl | Trazodone Hcl | 87 | 16 |
| Metformin Hcl | Metformin Hcl | 86 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 81 | suppressed |
| Bupropion Xl | Bupropion Hcl | 79 | 17 |
| Cephalexin | Cephalexin | 77 | 43 |
| Myrbetriq | Mirabegron | 74 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 73 | 13 |
| Klor-Con M20 | Potassium Chloride | 70 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 12 |
| Bumetanide | Bumetanide | 65 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Mirtazapine | Mirtazapine | 64 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 63 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Alprazolam | Alprazolam | 60 | 12 |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 15 |
| Betamethasone Valerate | Betamethasone Valerate | 54 | 35 |
| Amoxicillin | Amoxicillin | 53 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Colchicine | Colchicine | 46 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Torsemide | Torsemide | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 16 |
| Diclofenac Potassium | Diclofenac Potassium | 39 | 12 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Latanoprost | Latanoprost | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 20 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Fluconazole | Fluconazole | 29 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 20 |
| Valproic Acid | Valproic Acid | 28 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Acetic Acid | Acetic Acid | 26 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 26 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Eplerenone | Eplerenone | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 21 |
| Risperdal Consta | Risperidone Microspheres | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 13 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Clobazam | Clobazam | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.11 · 3 records | Lilly USA, LLC | AREXVY, GVOKE HYPOPEN, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error